Tilray | TRLY - Operating Profit

Stock Price
10.85
Daily Change
0.49 4.73%
Monthly
-9.88%
Yearly
835.34%
Q1 Forecast
10.37

Tilray reported $-20.01M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acasti Pharma USD -2.53M 560K Sep/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
Avita Medical AUD -11.15M 1.19M Jun/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Cronos Group USD 55.24M 59.63M Sep/2025
Dianthus Therapeutics USD -40.29M 5.36M Sep/2025
Divis Laboratories Ltd INR 7.72B 30M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
IQVIA Holdings USD 2.68B 2.1B Dec/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Moderna USD -857M 597M Dec/2025
Organigram Holdings CAD -28.05M 7.76M Sep/2025
Organon & Co USD 388M 62M Sep/2025
Revvity USD 145.83M 47.49M Dec/2025
Tectonic Therapeutic USD -21.89M 440K Sep/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD 234.5M 49.1M Sep/2025
Xeris Pharmaceuticals USD 6.73M 2.25M Sep/2025